Human tumor infiltrating lymphocytes cooperatively regulate prostate tumor growth in a humanized mouse model
出版年份 2015 全文链接
标题
Human tumor infiltrating lymphocytes cooperatively regulate prostate tumor growth in a humanized mouse model
作者
关键词
NOD/SCID/IL-2Rγnull, Human prostate cancer, Tumor infiltrating lymphocyte, Humanized
出版物
Journal for ImmunoTherapy of Cancer
Volume 3, Issue 1, Pages -
出版商
Springer Nature
发表日期
2015-04-03
DOI
10.1186/s40425-015-0056-2
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- CD8+ Tumor-Infiltrating T Cells Are Trapped in the Tumor-Dendritic Cell Network
- (2015) Alexandre Boissonnas et al. NEOPLASIA
- Long-Term Engraftment and Expansion of Tumor-Derived Memory T Cells Following the Implantation of Non-Disrupted Pieces of Human Lung Tumor into NOD-scid IL2R null Mice
- (2014) M. R. Simpson-Abelson et al. JOURNAL OF IMMUNOLOGY
- Higher susceptibility of NOD/LtSz-scid Il2rg-/- NSG mice to xenotransplanted lung cancer cell lines
- (2014) Nobuhiro Kanaji et al. Cancer Management and Research
- Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
- (2013) S. F. Slovin et al. ANNALS OF ONCOLOGY
- A role for miR-155 in enabling tumor-infiltrating innate immune cells to mount effective antitumor responses in mice
- (2013) E. Zonari et al. BLOOD
- Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer
- (2013) A N Seo et al. BRITISH JOURNAL OF CANCER
- Specific Recruitment of Regulatory T Cells in Human Breast Cancer
- (2013) J. Ye et al. CANCER RESEARCH
- Humanized mice: novel model for studying mechanisms of human immune-based therapies
- (2013) Louis Gonzalez et al. IMMUNOLOGIC RESEARCH
- Exploiting the curative potential of adoptive T-cell therapy for cancer
- (2013) Christian S. Hinrichs et al. IMMUNOLOGICAL REVIEWS
- Tumor-Infiltrating Regulatory T Cells Inhibit Endogenous Cytotoxic T Cell Responses to Lung Adenocarcinoma
- (2013) A.-P. Ganesan et al. JOURNAL OF IMMUNOLOGY
- Expression of Leukotriene B4 Receptor-1 on CD8+ T Cells Is Required for Their Migration into Tumors To Elicit Effective Antitumor Immunity
- (2013) R. K. Sharma et al. JOURNAL OF IMMUNOLOGY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model
- (2012) P. Yu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity
- (2011) Caroline Jochems et al. EXPERIMENTAL BIOLOGY AND MEDICINE
- Humanized tumor mice-A new model to study and manipulate the immune response in advanced cancer therapy
- (2011) Anja K. Wege et al. INTERNATIONAL JOURNAL OF CANCER
- Lineage-specific T-cell reconstitution following in vivo CD4+ and CD8+ lymphocyte depletion in nonhuman primates
- (2010) J. C. Engram et al. BLOOD
- CD8+ Cell Depletion Accelerates HIV-1 Immunopathology in Humanized Mice
- (2010) S. Gorantla et al. JOURNAL OF IMMUNOLOGY
- Reconstitution of huPBL-NSG Mice with Donor-Matched Dendritic Cells Enables Antigen-Specific T-cell Activation
- (2010) Airi Harui et al. Journal of Neuroimmune Pharmacology
- Cutting Edge: Tumor-Specific CD8+ T Cells Infiltrating Prostatic Tumors Are Induced to Become Suppressor Cells
- (2009) K. A. Shafer-Weaver et al. JOURNAL OF IMMUNOLOGY
- Broad influenza-specific CD8+ T-cell responses in humanized mice vaccinated with influenza virus vaccines
- (2008) C. I. Yu et al. BLOOD
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More